GlassScriptPhysician profile
Rajat Kaul
NPI 1932275013
$2,956.44
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,039 · 2021: $671 · 2022: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $456.75 | 2019-2021 | |
| Amgen INC. | $362.28 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $354.71 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $227.47 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $208.83 | 2021 | |
| Akebia Therapeutics INC | $196.49 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $169.90 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $160.59 | 2019 | |
| Vifor Pharma, INC. | $160.18 | 2019-2021 | |
| Daiichi Sankyo INC. | $107.19 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $101.83 | 2019-2022 | |
| Horizon Therapeutics Plc | $81.76 | 2019-2021 | |
| Shire North American Group INC | $59.74 | 2019 | |
| Melinta Therapeutics, LLC | $53.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.50 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $37.09 | 2019 | |
| Genentech USA, INC. | $32.84 | 2019 | |
| Glaxosmithkline, LLC. | $28.67 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.03 | 2020 | |
| Amicus Therapeutics, INC. | $21.38 | 2022 | |
| Novo Nordisk INC | $21.04 | 2021 | |
| Aurinia Pharma U.S., INC. | $16.93 | 2022 | |
| Medtronic, INC. | $15.83 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.57 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.